Maravai Lifesciences Holdings (MRVI) Accumulated Expenses (2020 - 2026)

Maravai Lifesciences Holdings' Accumulated Expenses history runs 7 years deep, the most recent figure standing at $28.6 million for Q1 2026.

• On a quarterly basis, Accumulated Expenses fell 35.77% year-over-year to $28.6 million in Q1 2026; TTM through Mar 2026 was $28.6 million, a 35.77% decrease from a year earlier, with the FY2025 full-year figure at $36.6 million, down 7.6% from the prior year.
• Accumulated Expenses slipped to $28.6 million in Q1 2026 per MRVI's latest filing, from $36.6 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $70.1 million in Q1 2023 and bottomed at $28.6 million in Q1 2026.
• The 5-year median for Accumulated Expenses is $44.6 million (2025), against an average of $46.4 million.
• Across the five-year window, Accumulated Expenses soared 116.18% in 2023 and plunged 49.47% in 2024, its largest moves.
• Year by year, Accumulated Expenses stood at $53.4 million in 2022, then gained by 12.86% to $60.2 million in 2023, then slumped by 34.3% to $39.6 million in 2024, then retreated by 7.6% to $36.6 million in 2025, then declined by 21.66% to $28.6 million in 2026.
• Per Business Quant, the three latest MRVI Accumulated Expenses figures stand at $28.6 million (Q1 2026), $36.6 million (Q4 2025), and $48.1 million (Q3 2025).